No Data
AstraZeneca Earnings Expected to Rise With Focus on China -- Earnings Preview
Report Says 25% Pharma Tariff Would Raise US Drug Prices by $51 Billion Annually, Reuters Reports
Puma Biotechnology Presents Clinical Data Of Phase I Trial Of Trastuzumab Deruxtecan In Combination With Neratinib In Solid Tumors With HER2 Alterations At AACR 2025
SOPHiA GENETICS Announces Expanded Collaboration With AstraZeneca to Accelerate Liquid Biopsy Testing Globally From AACR
HSBC Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $79
J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)